Bio-Techne Corporation (TECH)

Market Cap	11.63B
Revenue (ttm)	1.17B
Net Income (ttm)	150.68M
Shares Out	158.89M
EPS (ttm)	0.95
PE Ratio	77.07
Forward PE	37.97
Dividend	$0.32 (0.44%)
Ex-Dividend Date	Nov 8, 2024

Volume	1,631,989
Open	71.25
Previous Close	71.39
Day's Range	71.25 - 74.27
52-Week Range	61.16 - 85.57
Beta	1.27
Analysts	Buy
Price Target	82.00 (+12.07%)
Earnings Date	Jan 30, 2025

About TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera,...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 9, 1989
• Employees: 3,050
• Stock Exchange: NASDAQ
• Ticker Symbol: TECH
• Website: https://www.bio-techne.com

Financial Performance

In 2024, Bio-Techne's revenue was $1.16 billion, an increase of 1.97% compared to the previous year's $1.14 billion. Earnings were $168.07 million, a decrease of -41.07%.

Analyst Forecast

According to 8 analysts, the average rating for TECH stock is "Buy." The 12-month stock price forecast is $82.0, which is an increase of 12.07% from the latest price.

Price Target

$82.0

(12.07% upside)

Analyst Consensus: Buy